We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanotubes a Source of MRI Contrast Agents

By Biotechdaily staff writers
Posted on 02 Sep 2005
Carbon nanotubes have become an unanticipated source of very effective contrast agents for enhancing magnetic resonance imaging (MRI) scans. More...


The new agents, called gadonanotubes, use the same very toxic metal, gadolinium, that is administered to more than one-fourth of MRI patients currently scanned with MRI, but the metal atoms are enclosed inside a hollow nanotube of pure carbon. Blanketing the toxic metals inside the harmless carbon is expected to considerably reduce or eliminate the metal's toxicity to patients.

The gadonanotubes were created by scientists from the Rice University (Houston, TX, USA), Baylor College of Medicine (Houston, TX, USA), and the University of Houston (TX, USA), and the Ecole Polytechnique Fédérale de Lausanne (Switzerland). They have succeeded in creating a new class of MRI contrast agents that are at least 40 times more effective than the best in current clinical use.

The study was published in the August 2005 issue of the journal Chemical Communications. "In prior work, we have boosted the effectiveness of gadolinium MRI contrast agents by encasing them in spheres of carbon called buckyballs,” said Dr. Lon Wilson, professor of chemistry at Rice and lead author of the study. "Each nanotube will hold more gadolinium atoms than a buckyball, so we expected them to be more effective agents. But they are actually much, much better than we anticipated, so much so that no existing theory can explain how they work.”

Dr. Wilson and coworkers used short segments of nanotubes, tiny tubes of pure carbon about one billionth of a meter, or 1 nm, in diameter, which is approximately as wide as a strand of DNA. The very short segments are only about 20-100 times longer than they are wide, and once inside the nanotubes, the gadolinium atoms naturally amass into tiny clusters of about 10 atoms each. The researchers suspect the clustering is causing the unexplained increases in magnetic and MRI effects that they noted in tests at Rice, at the University of Houston's Texas Center for Superconductivity, and in the Swiss laboratories.

These contrast agents increase the sensitivity of the scans, making it easier to obtain a diagnosis. Gadolinium agents are the most effective agents and the most typically used. The investigators hope in the near future to use existing methods of attaching disease-specific antibodies and peptides to gadonanotubes so they can be targeted to cancerous tumors and other diseased cells.





Related Links:
Rice University
Baylor College of Medicine

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.